Osteoarthritis Market to Grow Rapidly During the Forecast Period (2019-2032) -DelveInsight | Key Companies - Techfields Pharma, K-STEMCELL, and Several Others.

DelveInsight's Osteoarthritis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Osteoarthritis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Osteoarthritis Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

Download Sample Report @ https://www.delveinsight.com/sample-request/osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Osteoarthritis: An Overview
Osteoarthritis, also known as a degenerative joint disease (DJD), is the most common form of arthritis. Osteoarthritis is more likely to develop as people age. The changes in osteoarthritis usually occur slowly over many years, though there are occasional exceptions. Osteoarthritis affecting millions of people lie worldwide. It occurs when the protective cartilage that cushions the ends of the bones wears down over time. Although osteoarthritis can damage any joint, the disorder most commonly affects joints in your hands, knees, hips and spine. Approximately 80% of older adults have osteoarthritis, ages 55 years and older, have evidence of osteoarthritis.
Approximately 60% experience symptoms and symptoms worsen over time like Pain, Stiffness, Tenderness, Loss of flexibility, Grating sensation, Bone spurs and Swelling. Eventually, if the cartilage wears down completely, bone will rub on bone. Osteoarthritis has often been referred to as a wear and tear disease. But besides the breakdown of cartilage, osteoarthritis affects the entire joint. It causes changes in the bone and deterioration of the connective tissues that hold the joint together and attach muscle to bone. It also causes inflammation of the joint lining.

Osteoarthritis Market Drugs
This segment of the Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

View Detailed Research Report Here @ https://www.delveinsight.com/report-store/osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Osteoarthritis Emerging Drugs
Ampion: Ampion Pharmaceuticals
Ampion is a novel biologic drug containing a blood-derived cyclized peptide and small molecules that target multiple pathways in the innate immune response characteristic of inflammatory disease. Ampio is a non-steroidal anti-inflammatory drug that appears to have a significant role in the inflammatory conditions, including osteoarthritis, respiratory illness, and other inflammatory diseases. A Phase III clinical trial, AP-013 study was designed to confirm the efficacy observed in the first pivotal trial, AP-003-A, and was powered to detect treatment differences between Ampion and saline control. The AP-013 study was initiated in June 2019 and was ongoing when the COVID-19 outbreak occurred, which resulted in a large amount of missing data due to the pandemic. In March 2021, positive data from the modified Intent-to-Treat (mITT) population in the Company's AP-013 study, a Phase III clinical trial of the company's lead candidate, Ampion™, in patients suffering from severe osteoarthritis of the knee (OAK).

Lorecivivint: Biosplice Therapeutics
Lorecivivint (SM04690) is a small‐molecule CDC-like kinase 2 (CLK2) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) currently in development as a potential DMOAD for the treatment of knee OA. Company is conducting two large phase III clinical trials. Company hopes to demonstrate reduction in knee osteoarthritis pain with a single injection over the course of 6 months and 12 months, with follow-up beyond a year. Biosplice is also exploring the impact lorecivivint plays on inflammation, function, and cartilage protective effects through patient reported outcomes and structural endpoints.

X0002: Techfields Pharma
X0002 is a new anti-inflammatory drug that acts as an inhibitor of Cyclooxygenase. The FDA has granted the Fast Track Designation to X0002 for Knee Osteoarthritis and the low back. A Phase III, multicenter, double-blind, open-label, 22-Week and 30-week study is ongoing to evaluate the efficacy, safety, and pharmacokinetics of X0002 spray in relief of the pain for subjects with Osteoarthritis of the knee.

TLC599: Taiwan Liposomal Company
TLC599 is proprietary Bio Seizer formulation of dexamethasone sodium phosphate (DSP). BioSeizer formulation of dexamethasone sodium phosphate (DSP) is designed to provide sustained pain management for up to 24 weeks. In a Phase II trial, a single intra-articular injection of TLC599 resulted in statistically significant and clinically meaningful improvement in pain relief as compared to placebo from Day 3 all the way through the end of the study at 24 weeks in both the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS) scores.

MIV-711: Medivir AB
MIV-711 is a Cathepsin K inhibitor, that breakdown the collagen, a protein that plays an important role in the structural integrity of both bone and cartilage. MIV-711 has already been received Fast Track designation as a disease-modifying agent for osteoarthritis from FDA. Phase II data provides good support for further clinical development of MIV-711 as a disease-modifying treatment for osteoarthritis. In preclinical studies, MIV-711 has demonstrated that inhibition of cathepsin K can reduce the rate of joint destruction of osteoarthritis, and these findings have now been supported in clinical studies.

Read Full Research Report @ https://www.delveinsight.com/report-store/osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Osteoarthritis Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Osteoarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Osteoarthritis.

Prominent companies such as Amplicore Pharma, Peptinov, Novartis, Galapagos, AKL Research and Development, Ampio Pharmaceuticals, Techfields Pharma, Bone Therapeutics and others are developing potential drug candidates to boost the Osteoarthritis treatment scenario.

In April 2021, Ampio Pharmaceuticals announced that it had received a positive response from the U.S. Food and Drug Administration (FDA) on its plans for its AP-013 Phase III trial for the intra-articular injection of Ampion, its novel anti-inflammatory, for patients suffering from severe osteoarthritis of the knee (OAK).

In October 2020, Merck KGaA entered into an out-licensing agreement with Novartis for the development of of M6495, an anti-ADAMTS5 Nanobody for the potential treatment of osteoarthritis (OA). Anti-ADAMTS5 Nanobody program is Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain.

Osteoarthritis Companies include-
Techfields Pharma
K-STEMCELL
Taiwan Liposomal Company
Ampio Pharmaceuticals
Biosplice Therapeutics
Symic Bio
Gwo Xi Stem Cell Applied Technology
UnicoCell Biomed
Shionogi
Eli Lilly and Company
Xalud Therapeutics
ICM Biotech
Centrexion Therapeutics
AstraZeneca
Merck KGaA
Novartis
Antibe Therapeutics
Bioventus
PMG Pharm
Meluha Life Sciences SDN BHD
Meluha Life Sciences SDN BHD
Anika Therapeutics
Meiji Seika Pharma
Peptinov
OrthoTrophix
CartilaGen
MiMedx Group
Medivir
Orient Europharma Co
HSRx Biopharmaceutical, and Several Others

Request for more information @ https://www.delveinsight.com/sample-request/osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Key Insights
2. Executive Summary of Osteoarthritis
3. Competitive Intelligence Analysis for Osteoarthritis
4. Osteoarthritis: Market Overview at a Glance
5. Osteoarthritis: Disease Background and Overview
6. Patient Journey
7. Osteoarthritis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Osteoarthritis Unmet Needs
10. Key Endpoints of Osteoarthritis Treatment
11. Osteoarthritis Marketed Products
12. Osteoarthritis Emerging Therapies
13. Osteoarthritis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Osteoarthritis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get in touch with Business Expert @ https://www.delveinsight.com/report-store/osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.